JP7305664B2 - タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体 - Google Patents

タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体 Download PDF

Info

Publication number
JP7305664B2
JP7305664B2 JP2020545293A JP2020545293A JP7305664B2 JP 7305664 B2 JP7305664 B2 JP 7305664B2 JP 2020545293 A JP2020545293 A JP 2020545293A JP 2020545293 A JP2020545293 A JP 2020545293A JP 7305664 B2 JP7305664 B2 JP 7305664B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
alkoxy
compound
haloc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514999A5 (cg-RX-API-DMAC7.html
JP2021514999A (ja
Inventor
エミリア ディ フランチェスコ マリア
ジョーンズ フィリップ
ミッカフース ティモシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2021514999A publication Critical patent/JP2021514999A/ja
Publication of JP2021514999A5 publication Critical patent/JP2021514999A5/ja
Application granted granted Critical
Publication of JP7305664B2 publication Critical patent/JP7305664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020545293A 2018-03-01 2019-03-01 タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体 Active JP7305664B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637147P 2018-03-01 2018-03-01
US62/637,147 2018-03-01
PCT/US2019/020395 WO2019169326A1 (en) 2018-03-01 2019-03-01 Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

Publications (3)

Publication Number Publication Date
JP2021514999A JP2021514999A (ja) 2021-06-17
JP2021514999A5 JP2021514999A5 (cg-RX-API-DMAC7.html) 2022-02-17
JP7305664B2 true JP7305664B2 (ja) 2023-07-10

Family

ID=67767960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020545293A Active JP7305664B2 (ja) 2018-03-01 2019-03-01 タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体

Country Status (8)

Country Link
US (2) US11028083B2 (cg-RX-API-DMAC7.html)
EP (1) EP3758698A4 (cg-RX-API-DMAC7.html)
JP (1) JP7305664B2 (cg-RX-API-DMAC7.html)
CN (1) CN111867584A (cg-RX-API-DMAC7.html)
AU (1) AU2019226585A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017541A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092579A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019169326A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017541A2 (pt) 2018-03-01 2020-12-22 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt
WO2022192527A1 (en) * 2021-03-12 2022-09-15 Board Of Regents, The University Of Texas System Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153100A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20140315904A1 (en) 2013-03-14 2014-10-23 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044626A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044585A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
EP2221053A1 (de) * 2009-02-20 2010-08-25 Albert-Ludwigs-Universität Freiburg Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
US9593109B2 (en) * 2011-08-26 2017-03-14 Cymabay Therapeutics, Inc. Bicyclic agonists of GPR131 and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9133189B2 (en) * 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2903394C (en) * 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム,インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
EP2970181B1 (en) * 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US20170283400A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044576A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
WO2017136699A1 (en) 2016-02-05 2017-08-10 Epizyme, Inc Arginine methyltransferase inhibitors and uses thereof
KR102148587B1 (ko) 2016-02-23 2020-08-26 화이자 인코포레이티드 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
BR112020017541A2 (pt) 2018-03-01 2020-12-22 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153100A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20140315904A1 (en) 2013-03-14 2014-10-23 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044626A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044585A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof

Also Published As

Publication number Publication date
BR112020017541A2 (pt) 2020-12-22
EP3758698A1 (en) 2021-01-06
WO2019169326A1 (en) 2019-09-06
CN111867584A (zh) 2020-10-30
US11028083B2 (en) 2021-06-08
US20190270739A1 (en) 2019-09-05
CA3092579A1 (en) 2019-09-06
AU2019226585A1 (en) 2020-10-08
US20230027126A1 (en) 2023-01-26
EP3758698A4 (en) 2021-10-20
US11725008B2 (en) 2023-08-15
JP2021514999A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
AU2019263294B2 (en) Substituted heterocyclic inhibitors of PTPN11
US12186324B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
AU2017371084A1 (en) Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
WO2009032754A2 (en) Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
US20190308978A1 (en) Imidazopiperazinone inhibitors of transcription activating proteins
WO2021108198A1 (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease
AU2021355480B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
US20180057507A1 (en) Inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
JP2022553273A (ja) 疾患の治療のための二重ロイシンジッパー(dlk)キナーゼのビシクロ[1.1.1]ペンタン阻害剤
US11725008B2 (en) Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
WO2022192527A1 (en) Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
WO2026072966A2 (en) Pi3k degrader compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230628

R150 Certificate of patent or registration of utility model

Ref document number: 7305664

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150